Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G2A | P14555 | 17/20 | 0.51 |
| ▸ | HTR6 | P50406 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.37 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.37 |
| ▸ | PLA2G5 | P39877 | 1/20 | 0.37 |
| ▸ | PLA2G2E | Q9NZK7 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6691719 | 0.93 | PLA2G2A (0.49) | PLA2G2AHTR6 | |
| SCHEMBL5864626 | 0.92 | PLA2G2A (0.48) | PLA2G2AHTR6 | |
| SCHEMBL5508890 | 0.84 | PLA2G2A (0.55) | PLA2G2APLA2G10PLA2G1BPLA2G5PLA2G2E | |
| SCHEMBL14598621 | 0.84 | PLA2G2A (0.52) | PLA2G2AHTR6 | |
| SCHEMBL6694132 | 0.84 | PLA2G2A (0.46) | PLA2G2AHTR6 | |
| SCHEMBL5505563 | 0.83 | PLA2G2A (0.60) | PLA2G2APLA2G10PLA2G1BPLA2G5PLA2G2E | |
| SCHEMBL6694131 | 0.80 | HTR6 (0.51) | PLA2G2AHTR6PLA2G10 | |
| SCHEMBL5507320 | 0.80 | PLA2G2A (0.59) | PLA2G2APLA2G10PLA2G1BPLA2G5PLA2G2E | |
| SCHEMBL6129645 | 0.79 | FABP4 (0.43) | PLA2G2AHTR6 | |
| SCHEMBL5864649 | 0.78 | PLA2G2A (0.43) | PLA2G2AHTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7160909-B2 | Cyclopenta[b]indole derivatives as sPLA2 inhibitors | ELI LILLY AND COMPANY (US) | 2007-01-09 | — | — | US | disclosed |
| US-7160909-B2 | Cyclopenta[b]indole derivatives as sPLA2 inhibitors | ELI LILLY AND COMPANY (US) | 2007-01-09 | — | — | US | disclosed |
| US-20050026988-A1 | Cyclopenta'b! indole derivatives as spla inhibitors | KINNICK MICHAEL DEAN (US) | 2005-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050026988-A1 | Cyclopenta'b! indole derivatives as spla inhibitors | PTGIS, PLA2G4A, PLA2G4B | PLA2G2A 28/4885HTR6 641/4885KDM4E 4271/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.